Raytheon Technologies (RTX) has won a fresh missile defense contract from the Pentagon, adding to its backlog of advanced air-defense systems. Analysts note the stock may be trading at a 3% discount to intrinsic value despite the contract win.
RTX Lands Fresh Missile Defense Contract—Stock Undervalued
Raytheon Technologies' latest defense win signals sustained Pentagon spending momentum.

| Ticker | Company | 1-year change |
|---|---|---|
| LMT | Lockheed Martin | +3.3% |
| NOC | Northrop Grumman | −16.6% |
| GD | General Dynamics | +9.0% |
| LHX | L3Harris | −0.0% |
RTX's missile defense contract validates Pentagon's sustained investment in air defense, supporting the stock's valuation.
Raytheon Technologies (RTX) is the direct beneficiary—the contract adds revenue and extends the company's defense backlog. Lockheed Martin LMT and Northrop Grumman NOC compete in adjacent missile-defense segments and face competitive pressure if RTX's contract signals Pentagon preference for Raytheon's systems. General Dynamics GD and L3Harris LHX supply components and subsystems to RTX and benefit from increased production rates.
No clear loser; this is a win for the defense industrial base. The risk is if Pentagon budget constraints force trade-offs between missile defense and other priorities—RTX's contract could cannibalize funding for competing programs.
Watch for RTX's Q1 2025 earnings call for contract details and backlog updates. If RTX raises full-year guidance or discloses additional missile-defense awards, the stock's valuation discount could narrow. Monitor defense budget appropriations; if Congress approves higher missile-defense spending, RTX's upside expands.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.